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ABSTRACT

Compounds of the class of 4-oxo-butenoic acid derivatives
are disclosed along with the surprising use property of these
compounds as a anti-tumor agents in humans against breast
carcinoma, which include: 2-(N'-Fluoren-9-ylidenehydrazino )5,5-dimethyl-4-oxo-hex-2-enoic acid methyl
ester (OF-06), 1-(2,4-Dimethyl-phenyl)-2,4-dihydroxy-3( 4-methy 1-benzoy 1)-5-oxo-2,5-dihydro-lH-pyrrole-2carboxylic acid methyl ester (lF-07), 4-(4-Methoxyphenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid (3F10), 4-(4-Chloro-phenyl)-2,4-dioxo-3-(phenyl-hydrazono )butyric acid ethyl ester (3F-11), 2-Hydroxy-4-oxo-4-(2,3,5,
6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15),
and 4,4-Dihydroxy-5-( 4-methyl-benzoyl)-2-phenyl-2,4dihydro-pyrazol-3-one (3F-16) as well as some novel
derivatives of these compounds claimed (see Table 2). The
invention also encompasses a class of the compounds with
the novel property of anti-tumor activity against human
breast cancer, which includes the following compounds
4-( 4-Ethoxy-pheny1)-2-(N'-fiuoren-9-ylidene-hydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-{N'-[1(4-Chloro-phenyl)-ethylidene ]-hydrazino }-4-oxo-4-phenylbut-2-enoic acid methyl ester (OF-20); 2-(N'-Fluoren-9ylidene-hydrazino )-4-oxo-4-phenyl-but-2-enoic acid methyl
ester (lF-04); and 4-Chloro-4-( 4-ethoxy-phenyl)-2(fiuoren-9-ylidene-hydrazono)-but-3-enoic acid methyl
ester (3F-19).

2 Claims, 2 Drawing Sheets
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TREATMENT OF BREAST CANCER

2

derivatives of carboxylic acid (column 9, line 31) and
pyrrolidine (column 7, line 24);
This application is a division of Ser. No. 10/164,541,
Brown (U.S. Pat. No. 6,066,670) describes an anti-viral
filed on Jun. 7, 2002, which claims benefit of Ser. No.
admixture containing crotonic acid for treating tumors
60/296,823, filed on Jun. 8, 2001.
(see Abstract);
5
Harwell, et al (U.S. Pat. No. 5,580,896) discloses many
FIELD OF THE INVENTION
4-oxo-2-butenoic acid derivatives (column 13, lines
This invention relates to novel 4-oxo-butenoic acid
21-59; also in columns 15+, examples 25,26,32,34,40,
derivatives and to the use of these compounds and related
43-46,77-79,97,99,103,106,), which are useful for
compounds with novel biological activity in humans as
inhibiting colorectal cancer, i.e., colon cancer
10
therapeutic means for the prevention and treatment of the
(Abstract); and,
human breast cancer and claims the benefit of priority of
Giordani, et al (U.S. Pat. No. 5,580,890) discloses 4-oxoU.S. Provisional Application Ser. No. 60/296,823 filed Jun.
2-butenoic acid derivatives said to be useful for treat8, 2001.
ment of AIDS (column 1, line 8 and column 2, line 61;
BACKGROUND OF THE INVENTION
and,
15
Yonemeto, et al (U.S. Pat. No. 6,083,985) recites a
Cancer is a global killer of humans with breast cancer
number of anti-tumor or anti-AIDS agents that include
among the leaders of killing humans yearly. Breast cancer is
butenoic acid derivatives.
the primary killer of women. One in eight American women
The U.S. patent literature has many disclosures of
will develop breast cancer in her lifetime. In 2001, an
estimated 192,700 women in the U.S. will be diagnosed with 20 butanoic acid derivatives including:
Nicolai, et al (U.S. Pat. No. 6,180,651) discloses many
invasive breast cancer and 42,600 with in situ (tumors
anti-inflammatory and analgesic compounds, including
contained in the milk ducts). An estimated 40,000 will die
adenocarcinoma (column 1, line 55), which includes
from the disease.
heterocyclic alcohol-esters (column 11, lines 1-16) and
An estimated 3 million women in the U.S. today are living
butanoic acid derivatives (many Examples including 47
with breast cancer of which 2 million have been diagnosed
through 162);
with the disease and 1 million have the disease but do not yet 25
Girard, et al (U.S. Pat. No. 5,308,852) discloses many
know it.
compounds including butanoic acid derivatives (see
The incidence of breast cancer in the U.S. has more than
Methods B and C of schemes II and III) which comdoubled in the past 30 years. In 1964, the lifetime risk was
pounds which are said to inhibit tumor metastasis
1 in 20. Today it's 1 in 8. Breast cancer is the most
(column 7, line 56 and column 8, line 4); and,
commonly diagnosed cancer in women in both America and 30
Frechette (U.S. Pat. No. 5,696,117), Frechette (U.S. Pat.
worldwide. Breast cancer rates are the highest in industriNo. 5,854,242) and Frechette (U.S. Pat. No. 5,707,990)
alized countries. It is estimated that 1.2 million new diagdescribe 148 benzoxazine and pyrido-oxazine heteronoses and 500,000 deaths from breast cancer will occur
cyclics as anti-bacterial compounds.
worldwide this year. Further, it appears that breast cancer is
It appears from the foregoing that the derivatives of
35
the leading cause of death for American women of ages 25
4-oxo-butanoic acid of interest are not disclosed and thus
to 55 years.
there is no report of their activity against human breast
No vaccine or other universally successful method for the
cancer.
prevention or treatment of breast cancer is currently availConsequently, there is a need for an anti-cancer drug for
able. Management of the disease currently relies on a
40 humans that mitigates the above mentioned disadvantages of
combination of early diagnosis (through routine breast
current drug therapy and effectiveness against human breast
screening procedures) and aggressive treatment, which may
cancer.
include one or more of a variety of treatments such as
SUMMARY OF THE INVENTION
surgery, radiotherapy, chemotherapy and hormone therapy.
The course of treatment for a particular breast cancer is often
The
first
objective of the present invention is to provide a
45
selected based on a variety of prognostic parameters, includdrug effective for treatment of human breast cancer.
ing an analysis of specific tumor markers. {Porter-Jordan
Another object of this invention is to provide novel
and Lippman, Breast Cancer 8:73-100 (1994)}. However,
4-oxo-butenoic acid derivatives.
the use of established markers often leads to a result that is
A further object of this invention is to provide 4-oxodifficult to interpret, and the high mortality observed in
50 butenoic acid derivatives with novel activity against human
breast cancer patients indicates that improvements are
breast cancer.
needed in the treatment, diagnosis and prevention of the
A preferred embodiment of the invention encompasses a
disease.
class of compounds having the property of anti-tumor activAccordingly, there is a need for improved methods for
ity against human breast cancer comprising the novel strucchemotherapy for breast cancer. The present invention ful- 55 tures of 4-oxo-butenoic derivatives and more specifically
fills this need and further provides other related advantages.
those derivatives: 2-(N'-Fluoren-9-ylidene-hydrazino)-5,5The U.S. patent literature has many disclosures of oxodimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06);
butenoic ( crotonic) acid derivatives:
1-(2,4-Dimethy 1-pheny 1)2,4-dihydroxy-3-( 4-methy lPamnukci (U.S. Pat. No. 6,232,312) describes crotonic
benzoyl)-5-oxo-2,5-dihydro-lH-pyrrole-2-carboxylic acid
acid derivatives (column 22, lines 43-58) for the treat- 60 methyl ester (lF-07); 4-( 4-Methoxy-phenyl)-2,4-dioxo-3ment of colonic polyps;
(phenyl-hydrazono )-butyric acid (3F-10); 4-(ChloroJones et al (U.S. Pat. No. 6,121,450) discloses crotonic
phenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid ethyl
acid derivatives (column 8, tine 34; column 78, line 24
ester (3F-11); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4and at example 34 as steroid modifiers in treating breast
methoxy-phenyl)-but-2-enoic acid (3F-15); and 4,4cancer (column 1, lines 55-58);
65 Dihydroxy-5-( 4-methy 1-benzoy1)-2-pheny1-2,4-dihydroKalden, et al (U.S. Pat. No. 5,334,612) discloses compyrazol-3-one (3F-16) as well as novel derivatives of these
pounds said to be useful for treating AIDS including
compounds (see Table 2).
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The use of the following compounds for humans as
therapeutic means for the eradication of human breast cancer
further encompasses the following: 4-( 4-Ethoxy-phenyl)-2(N'-fiuoren-9-y lidene-hydrazino )-2-hydroxy-4-oxo-butyric
acid methyl ester (OF-13); 2-{N'-[1-(4-Chloro-phenyl)- 5
ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidenehydrazono )-but-3-enoic acid methyl ester (3F-19).
10
Further objects and advantages of this invention will be
apparent from the following detailed description of presently
preferred embodiments, which are illustrated structurally in
the accompanying drawings.

the compound designated as lF-07 is 1-(2,4-Dimethylphenyl)-2,4-dihydroxy-3-( 4-methyl-benzoyl)-5-oxo-2,
5-dihydro-lH-pyrrole-2-carboxylic acid methyl ester;
the compound designated as 3F-10 is 4-(4-Methoxyphenyl)-2,4-dioxo-3-pheny1-hydrazono)-butyric acid
the compound designated as 3F-11 is 4-(4-Chlorophenyl)-2,4-dioxo-3-(phenyl-hydrazono )-butyric acid
ethyl ester;
the compound designated as 3F-15 is 2-Hydroxy-4-oxo4-(2,3,5,6-tetrafiuoro-4-methoxy-phenyl)-but-2-enoic
acid and,
the compound designated as 3F-16 is 4,4-Dihydroxy-5( 4-methyl-benzoy 1)-2-pheny1-2,4-dihydro-pyrazol-3one.
15
BRIEF DESCRIPTION OF THE FIGURES
These compounds have very high activity against human
breast cancer and a very low toxicity as Lethal Dose 50
FIG. 1 illustrates structurally a chemical compound des(LD 50) in animals. The percent activity and animal toxicity
ignated as OF-06.
for each compound is as follows:
FIG. 2 illustrates structurally a chemical compound des20
OF-06 (100% against human breast carcmoma and
ignated as lF-07.
LD 50 >3000 mg/kg);
FIG. 3 illustrates structurally a chemical compound deslF-07 (100% against human breast carcmoma and
ignated as 3F-10
LD 50 >500 mg/kg);
FIG. 4 illustrates structurally a chemical compound des3F-10
(100% against human breast carcmoma and
ignated as 3F-11
25
LD
<750 mg/kg);
50
FIG. 5 illustrates structurally a chemical compound des3F-11 (100% against human breast carcmoma and
ignated as 3F-15
LD 50 >2000 mg/kg);
FIG. 6 illustrates structurally a chemical compound des3F-15
(100% against human breast carcmoma and
ignated as 3F-16
LD 50 >200 mg/kg); and,
30
DESCRIPTION OF THE PREFERRED
3F-16 (100% against human breast carcmoma and
EMBODIMENTS
LD 50 >500 mg/kg)
Before explaining the disclosed embodiments of the
present invention in detail, it is to be understood that the
PREPARATION OF (OF-06)
invention is not limited in its application to the details of the 35
particular arrangement shown since the invention is capable
EXAMPLE 1
of other embodiments. Also, the terminology used herein is
The preparation of 2-(N'-Fluoren-9-ylidene-hydrazino)-5,
for the purpose of description and not of limitation.
5-dimethyl-4-oxo-hex-2-enoic acid methyl ester (OF-06). A
As earlier recited this application has been filed in order
to disclose: new 4-oxo-butenoic acids that have been found 40 solution of 5.0 g (0.02 moles) of 2-hydroxy-5,5-dimethyl4-oxo-hex-2-enoic acid methyl ester (1) (synthesis was
to have high activity against human breast cancer and low
previously published by E. Royals. JAm Chem.Soc., 1945,
toxicity in animals.
67, 1508) and 3.88 g (0.02 moles) of fiuoren-9-ylideneMore specifically this application is for the novel antihydrazine (2) in 80 mL of absolute toluene was refluxed for
tumor compounds OF-06, lF-07, 3F-10, 3F-11, 3F-15 and
3F-16 which have been structurally shown in FIGS. 1-6, 45 3 hr 30 min with a Dean-Stark trap (control for the end of
the reaction was carried by TLC). The solution was cooled
respectively, as well as novel derivatives of these comand the precipitate was filtered and recrystallized from
pounds claimed (see Table 2) and the activity against human
absolute benzene-hexane (1:1) to give 3.4 g (68% yield) of
breast cancer of compounds OF-13, OF-20, 1F04, and 3F-19
yellow
crystals, mp 135-137° C.
also as shown in Table 1 along with anti-tumor activity and
Solubility: highly soluble in DMSO, DMFA,
toxicity.
50
dichloroethane, acetonitrile, slightly soluble in ethanol,
To facilitate a full understanding of the invention:
tetrachloromethane, insoluble in hexane and water.
the compound designated as OF-06 is 2-(N'-Fluoren-9y lidene-hydrazino )-5,5-dimethy1-4-oxo-hex-2-enoic
The synthesis of OF-06 is an example of well known
acid methyl ester;
amination/dehydration reactions.

CH3

I
I

CH3-C-CO-CH=C-COOCH3
CH3
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+
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2
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PREPARATION OF (lF-07)

solution of 0.075 moles of 2-Hydroxy-4-( 4-methoxyphenyl)-4-oxo-but-2-enoic acid in 300 ml of dioxane small
EXAMPLE 2
potions of an aqueous solution prepared from 0.075 moles of
The preparation of 1-(2,4-Dimethyl-phenyl)-2,4aniline, 0.92 moles of sodium nitrate and 19 ml of concendihydroxy-3-( 4-methy 1-benzoy1)-5-oxo-2,5-dihydro-lH- 20 trated HCl in 90 ml of water (DI) was added. During cooling
pyrrole-2-carboxylic acid methyl ester (lF-07). To a solution
11.4 g of sodium acetate was added and the reaction was
of 1.65 g (0.0051 moles) of 2-(2,4-dimethyl-phenylamino)kept at the r.t. for 24 hr. Then 2 L of water was added to the
4-oxo-4-p-tolyl-but-2-enoic acid methyl ester (1) in 20 mL
reaction mixture and the resulting precipitate was filtrated
of anhydrous chloroform was added 0.68 g (0.0054 moles)
and recrystallized from 1: 1 mixture of dimethyl chloride/
oxalyl chloride. After refluxing for 30 min, 10 mL of 25 ethyl acetate to give 15.93 g of yellow crystals (60% yield)
anhydrous hexane was added and 15 ml of solvent was
with m.p. of 176-177 (decamp).
distilled out. The remainder of the solvent was evaporated
Solubility: highly soluble in DMSO, DMFA, slightly
by keeping the flask open for 12 hr. The resulting precipitate
soluble in chloroform, dichloroethane; insoluble in hexanes.
was filtered and recrystallized from dichloroethanetetrachlorometane (1:2) to give 1.25 g (62%) of compound 30
lF-7 in the form of white crystals, mp 133-135° C.
H3Co-O-co-cH=1-cooH +
(decamp.)
OH
Solubility: highly soluble in DMSO, acetonitrile, slightly
soluble in dichloroethane, benzene, insoluble in hexane
tetrachloromethane and water.
35
PREPARATION OF (3F-10)

H3C~COOCH3

1. (COC1)2, t
2. H10
40

n,c'Q
0

NH

H 3c o - O - c o - I T - c o - c o o H
N-NHC6Hs

3F-10

45

PREPARATION OF (3F-11)
CH3

EXAMPLE 4
The preparation of 4-( 4-Chloro-phenyl)-2,4-dioxo-3(phenyl-hydrazono )-butyric acid ethyl ester (3F-11). A solution of 0.5 g (0.0016 moles) of 5-(4-Chloro-benzoyl)-2phenyl-2H-pyrazole-3,4-dione (1) (synthesis was previously
published by Pimenova, E. V.; Andreichikov, Yu. S. (1992)
Zh. Org. Khim. 28, 376-89), in 2 mL of anhydrous ethanol
was refluxed for 1 hr. The resulting solution was cooled and
the precipitate was filtered to give 0.48 g (85% yield) of
yellow crystals with m.p. of 141-142° C. (decamp).
CH3

IF-7

PREPARATION OF (3F-10)
EXAMPLE 3
The preparation of 4-( 4-Methoxy-phenyl)-2,4-dioxo-3(phenyl-hydrazono)-butyric acid (3F-10). To a hot stirred

US 6,703,426 Bl
7
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-continued

by Pimenova, E. V ;Andreichikov, Yu. S. (992) Zh. Org.
Khim. 28, 376-89), and 5 mL of water (DI) was kept at the
rt until the solution became colorless and precipitate was
formed. The precipitate was filtered and recrystallized from
dichloroethane-water (10:1) to give 0.45 g (85%) of yellowbrown crystals, mp 134-135° C.

o-0-hmoc,n,
N-NHC6Hs

0

5

0

3F-11

PREPARATION OF (3F-15)
EXAMPLE 6
The preparation of 2-Hydroxy-4-oxo-4-(2,3,5,6tetrafiuoro-4-methoxy-phenyl)-but-2-enoic acid (3F-15). A 15
solution of sodium methoxide was prepared from 0.46 g (20
mmol) of sodium and 30 mL of absolute methanol by
addding small portions to a mixture of 6.35 g (10 mmol) of
1-pentafiuorophenyl-ethanone 1 and 3.54 g (10 mmol) of
dimethyl oxalate 2. After stirring the reaction for 24 hr at rt, 20
50 mL of 25% aqueous solution of HCl was added. The
resulting mixture was extracted with ether (240 mL),
washed by solution of brine and dried over anhydrous
3F-16
Na 2 S0 4 . The solvent was removed in vacuum and 10 mL of
saturated solution of NaOH in ethanol was added with 25
stirring. After 1 hr the reaction mixture was diluted with
water and acidified with H 2 S0 4 (10%) to obtain pH of 1-2.
Solubility: highly soluble in DMSO, dioxane, insoluble in
The resulting precipitate of 3F-15 was filtered and recryswater.
tallized from toluene to give 1.73 g (81 % yield) in the form
of white-yellow crystals, mp 155-156° C. (decamp.).
30
PREPARATION OF (OF-13)
C6Fs-CO-CH3

+

(COOCH3)2

1

2)HC1
3) NaOH/C2HsOH

2

EXAMPLE 8
35

F

F

H 3 C O * j CO-CH=1-cooH
OH

F

F
3F-15

PREPARATION OF (3F-16)
EXAMPLE 7

The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fiuoren-9ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl
40 4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
3.88 g (0.02 moles) of fiuorene-9-ylidene-hydrazine (2) in
80 mL of absolute benzene and absolute toluene (1:1) was
refluxed for 1 hr 30 m with a Dean-Stark trap (the end of the
reaction was determined by TLC), cooled and the precipitate
45
was filtered and recrystallized from benzene-diethyl etherhexane mixture (1:3:2) to give 2.65 g (53% yield) of
colorless crystals with mp 114-116° C.
50

The preparation of 4,4-Dihydroxy-5-(4-methyl-benzoyl)2-phenyl-2,4-dihydro-pyrazol-3-one (3F-16). A solution of
0.5 g (0.0017 moles) of 5-( 4-Methyl-benzoyl)-2-phenyl-2Hpyrazole-3,4-dione (1) (synthesis was previously published

Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in hexane. The compound is not stable in solutions and decomposes quickly
when the solution is heated or stored for a long time with the
formation of OF-12.

~COOCH3
C2HsO~

0

,,

+

OH

2
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-continued

OH

~COOCH3
C2HsO~
0

,__ _
NH

'N

~
OF-13

OF-12

It is seen from the above that (OF-13) is an intermediate

product during the synthesis of (OF-12).

30

PREPARATION OF (3F-19)
EXAMPLE 9
The preparation of 4 Chloro 4 (4 ethoxy phenyl) 2 (fiuoren
9 ylidene hydrazono) but 3 enoic acid methyl ester (3f-19)
to the solution of 10 g (0.0026 moles of 4 (4 Ethoxy phenyl)
2 (N' fiuoren 9 yliden hydrazine) 4-oxo-but-2-enoic acide

35

methyl ester (OF-12) (synthesis was previously published by
Konyukhova, N. A.; Krasnykh, 0. P.; Aliev, Z. G.;
Maslivets, A. N. Cehmistry ofHetorcyclic Compounds (New
York, N.Y., United States) (Translation of Khimiya
Geterotsiklicheskikh Soedineii) (2001), 37(6), 779-780) in
5 mL of anhydrous benzene 0.3935 g (0.0031 moles) oxalyl
chloride was added. The reaction mixture was refluxed for 1
hour 40 min, cooled, precipitate was filtered and recrystallized from absolute benzene to give 0.62 g (54%) of yellow
crystals, m.p. 163-163 (decom).

C2H50--o--CO-CH=1-coocH3

C2H50--o--CO-CH2-w-coocH3

NH

N

I

I

N

~

V----lJ

N

~

V----lJ

OF-12

(COCl)2!

Hsc20--0--l=cH-TI-coocH3
Cl

I

N

N

~

V----lJ
3F-19
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TABLE 1
Some Compounds of the Invention
Activity
(ATCC

#
OF13

Structure

OH

C2HsO~COOMe
0

NH....._

Name

HrB123)

LDso,
mg/kg

4-( 4-Ethoxy-phenyl)2-(N'-fluoren-9ylidene-hydrazino)-2hydroxy-4-oxo-butyric
acid methyl ester

100%

>1500

Miles et. al.
UCF-303A

2-{N' -[ 1-( 4-Chlorophenyl)-ethylidene ]hydrazino }-4-oxo-4phenyl-but-2-enoic
acid methyl ester

83%

>250

Miles et. al.
UCF-311C

2-(N'-Fluoren-9ylidene-hydrazino)-4oxo-4-phenyl-but-2enoic acid methyl ester

93%

>1000

Andrejchikov, Yurij S.; Maslivets,
Andrej N.; Krasnykh, Olga P.;

Reference

~

lJL--V
OF20

0

lF04

Aleksandrova, Galina A.; Vozhakova,
Alla V Russ. (1993), CODEN:

RUXXE7 RU 2003655 Cl 19931130
Application: RU 91-5013322 19910704.
/NH

0
N

eta
3F19

4-Chloro-4-( 4-ethoxyphenyl)-2-(fluoren-9ylidene-hydrazono )but-3-enoic acid

methyl ester

100%

>200

Konyukhova, N. A.; Krasnykh, 0. P.;
Aliev, Z. G.; Maslivets, A. N.
Chemistry of Heterocyclic Compounds
(New York, NY, United States)
(Translation of Khimiya
Getero-tsiklicheskikh Soedinenii)
(2001), 37(6), 779-780.
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TABLE 2

TABLE 2-continued

Derivatives of 3F-10 having potential anti-tumor activity

Derivatives of 3F-10 having potential anti-tumor activity
5

#

Structure

~

#

Name

#

3-[ (4-Chloro-phenyl)hydrazono ]-2,4-dioxo4-phenyl-butyric
acid methyl ester

5

OCH3

10

4-( 4-Chloro-phenyl)2,4-dioxo-3-(p-tolylhydrazono )-butyric
acid methyl ester

0
N....._

N....._

NH

Cl

¢

15

20

Cl

2

OCH3 3-[ (4-Chloro-phenyl)hydrazono ]-2,4-dioxo4-p-tolyl-butyric
acid methyl ester
0

I

NH

¢
CH3

OCH3
25

0

I

N....._

H3C

Name

Structure

NH

4-( 4-Chloro-phenyl)3-[ (4-methoxyphenyl)-hydrazono ]2,4-dioxo-butyric
acid methyl ester

N....._

¢

Cl

30

35

Cl

NH

¢
OCH3

OCH3 2,4-Dioxo-4-p-tolyl-3(p-tolyl-hydrazono)butyric acid methyl

3

40

7

OC2Hs

ester

0

I

N

H3C

¢

45

N....._

OCH3 3-[(4-Chloro-phenyl)hydrazono ]-4-(4methoxy-phenyl)2,4-dioxo-butyric acid
methyl ester
0

I

6

50

55

I

NH

¢
Cl

OC2Hs 2,4-Dioxo-3-(phenylhydrazono )-4-p-tol ylbutyric acid
ethyl ester
0

8

N....._

H3CO

NH

Cl

CH3

4

0

I

'-NH

60

65

4-( 4-Chloro-phenyl)2,4-dioxo-3-(phenylhydrazono )-butyric
acid ethyl ester

N....._

H3C

NH

6
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TABLE 2-continued

TABLE 2-continued
Derivatives of 3F-10 having potential anti-tumor activity

Derivatives of 3F-10 having potential anti-tumor activity
#

Structure

Name
2,4-Dioxo-phenyl-3(phenyl-hydrazono )butyric acid
methyl ester

9

5

#

Structure

Name

14

4-( 4-Fluoro-phenyl)2,4-dioxo-3-(phenylhydrazono )-butyric
acid methyl ester

10

F

2,4-Dioxo-3-(phenylhydrazono-4-p-tolylbutyric acid
methyl ester

NH

6

15

10

0

I
N......_

15
20

0

I
N
'NH

Cl
25

30
11

4-( 4-Bromo-phenyl)2,4-dioxo-3-(phenylhydrazono)-butyric
acid methyl ester

16

4-( 4-Chloro-phenyl)2,4-dioxo-3-(phenylhydrazono )-butyric
acid methyl ester

6

3-[ (4-Methoxyphenyl)-hydrazono ]2,4-dioxo-4-phenylbutyric acid
methyl ester

35
Br

40

12

OCH3 4-(4-Methoxy-phenyl)2,4-dioxo-3-(phenylhydrazono)-butyric
acid methyl ester
0

3-[ (4-Chloro-phenyl)hydrazono ]-2,4-dioxo4-phenyl-butyric
acid methyl ester

17

45

0

I
N......_
50

13

I

OCH3 4-( 4-Ethoxy-phenyl)2,4-dioxo-3-(phenylhydrazono)-butyric
acid methyl ester
0

N

'NH

6

55

NH

¢
Cl

60

65

CYTOTOXICITY ASSAY
The activity in human breast cancer of the novel compounds (as earlier reported) was realized by the following
procedure which determines the inhibitory effect of test
samples on the growth of human breast cancer cells.
(ATCC HTB123) The HTB123 cells are grown in RPMI
1640 media+10% Fetal bovine serum+4.5 g/L glucose+lO
mM HEPES+ 1.0 mM sodium pyruvate+ 1% Antibiotic/
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Antimycotic for approximately 48 hours at 37° C./5% C0 2
in the presence of the test compound.
Growth/Non-Growth of the cells (e.g., cell density) is
determined using Promega's MTS/PMS assay system. MTS
(3-( 4,5-dime thylthiazol-2-yl)-5-(3carboxymethoxypheny1)-2-(4-sulfopheny l)-2H-tetrazolium,
inner salt) is an aqueous compound that is reduced to soluble
formazan by the presence of NADH formed by dehydrogenases present within the HTB123 cells. The absorbance of
the formazan can be measured at 490 nm and is directly
proportional to the number of living cells present in the
culture. PMS (Phenazine Methosulfate) is added an electron
coupling reagent and greatly increases the rate of reduction.
To facilitate a full understanding of the procedure the
following definitions are offered:
Test wells-wells containing test sample and Diluted HTB
123 cells
Test values-absorbance of test wells
Blank wells-wells containing test sample and HTB 123
media (HHTB2-01S); used to obtain background absorbance due to test sample
Blank values-absorbance of blank wells.
Negative Control-maximal cell growth; results of test
samples will be expressed as a percent of the Negative

Health and has been widely used since 1968.) Averaged
lethal dose (LD 50) of the compound was computed using
results of experiments on 5-7 groups of animals using
method of Litchfield and Wilkinson. (Belenkii M. L. "Elements of quantative determination of the pharmacological
effect," Leningrad, 1963, 71 pages).

5

USE OF THE INVENTION FOR TREATMENT
OF HUMAN BREAST CANCER
10

The compounds of the invention, i.e. 4-oxo-butenoic
acids derivatives and more specifically those novel derivatives: 2-(N'-Fluoren-9-ylidene-hydrazino)-5,5-dimethyl-4oxo-hex-2-enoic acid methyl ester (OF-06); 1-(2,4Dimethy1-pheny1)-2,4-dihydroxy-3-(4-meth y1-benzoy1)-515 oxo-2,5-dihydro- lH-pyrrole-2-carboxy lic acid methyl ester
(lF-07); 4-( 4-Methoxy-pheny 1)-2,4-dioxo-3-(phenylhydrazono )-butyric acid (3F-10); 4-( 4-Chloro-phenyl)-2,4dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester (3F11); 2-Hydroxy-4-oxo-4-(2,3,5,6-tetrafiuoro-4-methoxy20 phenyl)-but-2-enoic acid (3F-15) and, 4,4-Dihydroxy-5-(4methyl-benzoyl)-2-phenyl-2,4-dihydro-pyrazol-3-one (3F16), as well as all novel derivatives of these compounds
claimed (see Table 2), and the additional compounds of
Table 1 with activity against human breast cancer which
~~
~ include the following compounds 4-( 4-Ethoxy-phenyl)-2(N'-fiuoren-9-y lidene-hydrazino )-2-hydroxy-4-oxo-butyric
Positive Control-known inhibitor of HTB123 cells; used to
acid methyl ester (OF-13); 2-{N'-[1-4-Chloro-phenyl)validate assay system
ethylidene ]-hydrazino }-4-oxo-4-phenyl-but-2-enoic acid
Matrix-solvent that the samples are prepared/diluted in
methyl ester (OF-20); 2-(N'-Fluoren-9-ylidene-hydrazino)Assay samples of similar origin and matrix (e.g., methanol extraction, methylene chloride extraction, water soluble 30 4-oxo-4-phenyl-but-2-enoic acid methyl ester (lF-04); and
4-Chloro-4-( 4-ethoxy-pheny 1)-2-( fiuoren-9-y lidenesamples, etc.) together on the same plate in order to reduce
hydrazono )-but-3-enoic acid methyl ester (3F-19).
the number of steps performed per plate.
Blank values will be determined for each sample to
All the compounds are unique in the in vitro treatment of
account for any color contribution due to the sample itself.
humans and can be used as therapeutic means for the
These blank wells must contain the same amount of sample 35 eradication of tumors from the human breast in a pharmaplus HTB123 media (no cells). After completion of MTS/
ceutical composition comprising a non-toxic effective
PMS reaction blank values will be subtracted from the test
amount of the referenced compound or a tautomeric form
value to obtain a net absorbance that will be used to calculate
thereof or a pharmaceutically acceptable salt thereof or
cell density.
pharmaceutically acceptable solvate thereof, and a pharmaAll results are based upon a comparison to the Negative 40 ceutically acceptable carrier thereof.
Control value of the plate. The Negative Control must
For administration to man in the curative or prophylactic
contain the same amount of matrix (e.g., solvent) to offset
treatment of human breast cancer in vitro dosages of comany destructive effect the matrix may have on the growth of
pounds of the invention will generally be in the range of
the HTB123 cells (allows for baseline values to be set).
from 5 to 500 mg daily for an average adult patient (70 kg).
For most samples, a HTB123 cell growth (diluted two to 45 Thus for a typical adult patient, individual tablets or capsules
four-fold, depending upon the appearance of the inoculum*)
contain from 2-500 mg of active compound, in a suitable
of approximately 48 hours followed by and incubation of 3
pharmaceutically acceptable vehicle or carrier, for adminishours with the MTS/PMS Reagent is optimal.
tration in single or multiple doses, once or several times per
*Due to the nature of the HrB123 cells it is very difficult to obtain accurate
day. Dosages for intraveneous, buccal or sublingual admincell densities. Continuation of the HrB123 cell line typically consists of the 50
istration will typically be within the range of from 5-1000
dilution of mature cells at two or three-fold into fresh media and growth at
37° C./5% C0 2 for two to three days.
mg per single dose as required. In practice the physician will
In order to establish the accuracy of this assay a Positive
determine the actual dosing regimen which will be most
Control consisting of 50 µM Methotrexate should not
suitable for an individual patient and it will vary with the
decrease the net absorbance to less than 90% of the Negative 55 age, weight and response of the particular patient. The above
Control (HTB123 cells are somewhat resistant to methotrdosages are exemplary of the average case but there can be
exate) is utilized.
individual instances in which higher or lower dosage ranges
may be merited, and such are within the scope of this
ANIMAL TOXCITY BIOASSAY
invention.
The maximum human non-toxic one time administration
Acute toxicity was studied on white mice of both sexes 60
dose for the compound(s) of the invention appears to range
with weight ranging between 18-26 grams under intraperifrom 100 to 1500 mg.
toneal injection of 2% solution of tested compound in starch
(the compound was dissolved in starch slime and injected on
For human use, the compounds of the invention can be
the basis of 0.1 ml of solution per 10 g of the animal weight.
administered alone or jointly, but will generally be adminEach dose was tested on the group of 6 animals that were 65 istered in admixture with a pharmaceutical carrier selected
with regard to the intended route of administration and
observed during 14 days period. (This method was approved
standard pharmaceutical practice. For example, they may be
by the Pharmacology committee of Russian Ministry of
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could be solved by total synthesis. The first total synthesis
administered orally, buccally or sublingually, in the form of
was finally reported in 1994 by the Holton group. Although
tablets containing excipients such as starch or lactose, or in
capasules or ovules either alone or in admixture with
three total syntheses have been subsequently achieved by
excipients, or in the form of elixirs or suspensions containothers, the Holton synthesis is the most efficient, but still
ing flavouring or colouring agents. The compounds may also 5 requires over 40 steps from camphor and provides an overall
be injected parenterally, for example intraveneously,
yield of approximately 2%.
intramuscularly, subcutaneously or intracoronarily. For
Taxol is perhaps best viewed as an exciting and valuable
parenteral administration, they are best used in the form of
lead in cancer chemotherapy. Although Taxol has extended
a sterile aqueous solution which may contain other
the life of many people, it is not a cure, and many patients
substances, for example enough salts or glucose to make the 10 develop resistance to it. Many tumor types show minimal or
solution isotonic with blood.
no response to Taxol, and there are solubility problems in
drug delivery.
The invention thus provides a method for the treatment of
breast carcinoma in a human mammal which comprises
Accordingly, there is a need in the art for improved
administering an effective, non-toxic, amount of a heteromethods for therapy and diagnosis of breast cancer. The
cyclic compound according to the invention or a tautomeric 15 present invention fulfills these needs and further provides
form thereof and/or a pharmaceutically acceptable salt
other related advantages. The animal toxicity bioassay data
thereof and/or a pharmaceutically acceptable solvate
indicated that LD 50 dose for all of the compounds are in the
thereof, to abreast carcinoma invaded human mammal in
range of 250-3000 mg/kg, which is much lower compare to
need thereof.
some of the most promising agents against breast cancer. For
20
example taxol intraperitoneal LD 50 dose in mice using the
ADVANTAGES OF THE INVENTION
same bioassay system is 218 mg/kg (JZKEDZ 6,1,1980),
which is almost a number of magnitude higher then some of
Breast cancer is a significant health problem for women in
the claimed compounds. Such a low toxicity dose of the
the United States and throughout the world. Although
advances have been made in detection and treatment of the 25 compounds claimed gives a strong potential for not to
having such a serious side effects as the most potential drugs
disease, breast cancer remains the second leading cause of
of the present time do. Secondly, more advantages from our
cancer-related deaths in women, affecting more than 180,
invention are the cheapness and the simplicity of the syn000 women in the United States each year. For women in
thesis of active compounds compare to the present drugs on
North America, the life-time odds of getting breast cancer
the
market. The synthesis of claimed compounds from
are now one in eight.
30
commercially available reagents takes four to five synthetic
No vaccine or other universally successful method for the
steps with overall yield in the range of 60--85%. Versus for
prevention or treatment of breast cancer is currently availexample taxol which takes minimum of 40 synthetic steps
able. The available drugs on the market have a variety of
with only 2% overall yield, which increases the price of the
strong side effects, high cost and complicated synthesis. For
compound dramatically.
example, Taxol is the most promising antitumor agent 35
Conclusion: Although the invented compounds have not
developed in the past three decades. It was approved by the
yet been tested clinically, one can see from the Table 1 that
FDA for the treatment of refractory ovarian cancer in
all of them posses at least 10 times lower acute toxicity
December, 1992, and was introduced into the marketplace in
compare to the most promising antitumor agent developed in
January, 1993 by Bristol-Myers Squibb Company (EMS)
operating under a Cooperative Research and Development 40 the past three decades, high activity values, ease of
synthesis, and cheap cost. All these advantages provide a
Agreement (CRADA) with the National Cancer Institute
potential for the development of new drugs for the preven(NCI). It was approved for the treatment of breast cancer in
tion or treatment of breast cancer.
1994, and is now in transition from second line to first line
While the invention has been described, disclosed, illustherapy. Worldwide sales of Taxol reached $1.2 billion in
1998. However, Preclinical development continued from 45 trated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
1977 until 1983, hampered by a number of obstacles,
of the invention is not intended to be, nor should it be
especially the formulation problem. Taxol is highly lipodeemed to be, limited thereby and such other modifications
philic and is insoluble in water. Finally, a vehicle consisting
or embodiments as may be suggested by the teachings herein
of a mixture of Cremophore EL (polyethoxylated caster oil),
ethanol and saline was chosen, but its toxicity was a sig- 50 are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
nificant problem in preclinical studies. The main side effects
We claim:
of this drug were found to be congenital malformation in the
1. A compound consisting of 4-( 4-Chloro-phenyl)-2,4fetus and reproductive disorders. The supply of Taxol was
dioxo-3-(phenyl-hydrazono )-butyric acid ethyl ester.
also a problem. To obtain Yew bark, the tree had to be killed.
2. A method of treating breast carcinoma in a human in
A large Pacific Yew two feet in diameter requires 200 years 55
need of such treatment comprising the steps of administering
to grow and yields about five pounds of bark. In extractions
to said human, in a systemic, in vitro manner, an anti-tumor
by Polysciences, then the only extraction contractor, a
effective amount of a compound of claim 1 having the
0.004% yield of Taxol was obtained. Furthermore, the
common property of anti-tumor activity against human
Pacific Yew was a scarce understory tree, and its extinction
and destruction of the old growth forests was threatened by 60 breast cancer.
the harvest. Few believed, because of the complexity of the
molecule, that the problem of a commercial supply of Taxol
* * * * *

